EAGLE PHARMACEUTICALS, INC. (EGRX) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenue:
Total revenue	316.6	171.5	187.8	195.9	213.3	236.7	189.5	66.2
Total revenue growth	84.6%	-8.7%	-4.1%	-8.2%	-9.9%	24.9%	186.1%
Operating expenses:
Cost of product sales	85.5	31.5	33.6	47.9	42.4	33.7	35.8
Cost of royalty revenue	9.5	10.7	11.8	13.0	19.5	23.5
Research and development	34.1	51.3	30.8	36.8	44.4	32.6	28.3	27.9
Selling, general and administrative	106.6	75.3	78.6	76.4	60.5	71.4	53.3	20.2
Total operating expenses	235.7	168.8	154.8	174.1	176.7	162.7
Income from operations	81.0	2.8	33.0	21.8	36.6	74.0	53.4	2.6
Operating margin	25.6%	1.6%	17.5%	11.1%	17.2%	31.3%	28.2%	3.9%
Interest income	0.3	0.6	0.6	2.2	0.2	0.1	0.1	0.0
Interest expense	-4.0	-1.6	-2.6	-2.7	-2.7	-1.1	0.0	0.0
Other income (expense), net	-15.8	-6.2	-8.3	0.7
Total other expense, net	-19.5	-7.3	-10.3	0.9	-2.6	-1.0	0.1	0.0
Income (loss) before income tax provision	61.4	-4.5	22.7	22.0	34.0	72.9	53.4	2.6
Income tax provision	-25.8	-4.1	-10.7	-7.7	-2.1	-21.0	28.0	0.0
Net income (loss)	35.6	-8.6	12.0	14.3	31.9	51.9	81.5	2.6

Earnings (loss) per share attributable to common stockholders:
Basic (in dollars per share)	$2.76	($0.66)	$0.89	$1.04	$2.16	$3.44	$5.24	$0.17
Diluted (in dollars per share)	$2.73	($0.66)	$0.87	$1.01	$2.09	$3.27	$4.96	$0.16

Weighted average number of common shares outstanding:
Basic (in shares)	12.9	13.1	13.5	13.8	14.8	15.1	15.5	15.3
Diluted (in shares)	13.1	13.1	13.8	14.1	15.3	15.9	16.4	16.3